Abstract
This review provides a pharmacological approach to combat Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) based on two comprehensive denominations which could be specifically intended for viral replication process by either inhibiting essential genomic viral enzymes or preventing viral entry to human cells. These denominations focused on immune therapies either to improve innate antiviral immune responses or to reduce impairment triggered by underactive inflammatory reactions. A variety of drug candidates are available which can inhibit SARS-CoV-2 infection and replication, comprising serine protease inhibitors: Transmembrane Orotease/Serine Subfamily member 2 (TMPRSS2), camostat mesylate, nafamostat mesylate, and angiotensin-converting enzyme inhibitors. This review is also concerned with identifying drugs and ongoing clinical trials with their mechanisms of action against SARS-CoV-2. Chloroquine and hydroxychloroquine, monoclonal antibody, off-label antiviral drugs, nucleotide analog remdesivir and broad-spectrum antiviral drugs also could be used as inhibitors of SARS-CoV-2. Moreover, non-steroidal anti-inflammatory drugs (NSAIDs), dexamethasone, and antiviral phytochemicals that are currently reachable, can prevent SARS-CoV-2 pandemic morbidity and mortality.
 Keywords: COVID-19; Antiviral drugs; NSAIDs; ACE2; Clinical trials
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
